XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details)
 1 Months Ended 6 Months Ended 12 Months Ended
Sep. 01, 2021
USD ($)
Jul. 06, 2021
USD ($)
Apr. 12, 2021
shares
Jan. 05, 2021
USD ($)
shares
Jan. 27, 2022
Apr. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jul. 31, 2020
USD ($)
Apr. 17, 2020
Jun. 30, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Feb. 01, 2022
USD ($)
Dec. 31, 2021
EUR (€)
Commitments and Contingencies (Details) [Line Items]                          
Employment agreement, description                 The Employment Agreement provided for a base salary of $120,000 and 152,619 of vested shares of the Company’s common stock in April 2020. In addition, Mr. Weisblum shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board of Directors (“Board”).        
License fee   $ 10,000           $ 10,000          
Commercial sale term                   10 years 10 years    
License agreement expire                   15 years 15 years    
Sublicense income, description                   The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product. The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product.    
License agreement, description                   the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b) $50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $15,625. At June 30, 2022, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $13,125 as reflected in the accompanying condensed consolidated balance sheets. the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b) $50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization expense of $4,375 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $15,625 as reflected in the accompanying consolidated balance sheets.    
Royalty payments, description                   Royalty Payments Terms:  (i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and    (ii)5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and (i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and    
Recognized amortization expenses                     $ 92,095    
Payment of sponsored research amount                     838    
Prepaid expenses – non-current                     11,034    
Non-refundable cash payment       $ 500,000           $ 500,000 $ 500,000    
Net sale percentage                   2.00% 2.00%    
Licensor share (in Shares) | shares     500 500           500 500    
Aggregate of converted shares (in Shares) | shares     625,000 625,000           625,000 625,000    
Revenue term       15 years           15 years 15 years    
Number of voting shares (in Shares) | shares                     20,000    
Reverse stock split vote, description                   In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment.Prior to the April 12, 2021, issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment.Prior to the April 12, 2021 issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.    
Deferred revenue                   $ 1,031,250 $ 1,031,250    
Cash received                   500,000 500,000    
Securities received                   531,250 531,250    
Recognized revenues                   34,375 68,750    
Recognized revenue                     68,750    
Revenue long term portion amounts                   $ 859,375 $ 893,750    
Consideration fee payable percentage                   110.00% 110.00%    
Upfront license fees           $ 50,000       $ 50,000 $ 50,000    
First commercial sale                   10 years 10 years    
Agreement shall expire                   15 years 15 years    
Recognized revenues                     $ 2,514    
Deferred revenue – current portion                 $ 72,102 72,102    
Deferred revenue long-term                     44,134    
Total fee                     507,602   € 433,885
Payment, description             In December 2020, the Company paid the first payment of $101,520 which was recorded to prepaid expense and other current assets – current of which approximately $22,318 was amortized in fiscal 2020. In September 2021, the Company notified Maastricht University of Netherlands for an early termination of this agreement. Maastricht University of Netherlands has not reached the second phase which is to obtain approval from ethical committee. The Company has no further obligation after the termination. During the year ended December 31, 2021, the Company amortized the remaining prepaid expense of $79,202.             
Sponsored study agreement, description       The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $40,737.                  
Sublicense amount paid                   $ 342,850 $ 342,850    
Sponsored research agreement, description                   The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021, third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022. The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021 which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. During the year ended December 31, 2021, the Company amortized $92,855 of the prepaid expense leaving a prepaid asset of $7,715 at December 31, 2021.    
Prepaid expense leaving a prepaid asset             $ 241,091     $ 99,939 $ 145,324    
Company paid cash $ 92,095                   5,000    
Payment of university                   5,000 $ 5,000    
Risk free interest rate                     0.50%    
Expected dividend yield                     0.00%    
Expected term                     5 years    
Expected volatility                     169.00%    
Deferred compensation balance                   35,782      
Prepaid expense and other current assets                   838 $ 838    
Prepaid expenses non-current                   10,615 11,034    
Non refundable fees                   2,500      
Deferred revenue current portion                   68,750 68,750    
Deferred revenue long-term portion                   42,458 $ 893,750    
Company paid second payment                       $ 50,000  
Agreement, description                     In 2021, the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company paid $10,000 related to this agreement.    
Minimum [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Salary was increased                   120,000 $ 120,000    
Maximum [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Salary was increased                   180,000 180,000    
Sublicense Agreement [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Sublicense income, percentage           25.00%              
Sublicense agreement amount paid           $ 12,500              
Recognized amortization expenses                     628    
Recognized revenues                   1,676 2,514    
Deferred revenue – current portion                     $ 3,352    
Amortization expense                   419      
Deferred revenue current portion                   $ 3,352      
Columbia University [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Sponsored research agreement, description                   If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded to prepaid expense and other current assets – current to be amortized over the estimated project timeline of twelve months. In 2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were $0 and $71,804, respectively. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded to prepaid expense and other current assets – current to be amortized over the estimated project timeline of twelve months. During the year ended December 31, 2021, the Company amortized $359,021 of the prepaid expense. As of December 31, 2021, prepaid expense related to the sponsored research agreement was $71,804.    
Prepaid expense leaving a prepaid asset                     $ 7,715    
Dr. James Kuo [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Employment agreement, description         James Kuo entered into an employment agreement (“Kuo Employment Agreement”) for Dr. Kuo to serve as the Vice President of Research & Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days’ prior to the applicable renewal date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (“Board”) and shall be payable at the Company’s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.                
Stock option (in Shares) | shares                   16,000      
Fair value of stock option                   $ 94,914      
Risk free interest rate                   1.18%      
Expected dividend yield                   0.00%      
Expected term                   2 years      
Expected volatility                   117.00%      
Fair value of the unvested stock option                   $ 59,322      
Stock-based Compensation                   23,540      
Deferred compensation balance                   35,782      
Aikido [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Deferred revenue current portion                     3,352    
Deferred revenue long-term portion                     44,134    
Master License Agreement [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Upfront license fees                   $ 1,900,000 $ 1,900,000    
JV Agreement [Member]                          
Commitments and Contingencies (Details) [Line Items]                          
Pursuant terms, description                   Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture. Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture.